BLOOD CANCER UNITED INC: Form 990, tax year 2019

View the entire original 990 at ProPublica ↗

Organization
BLOOD CANCER UNITED INC (EIN 13-5644916)
Tax period
2019-07-01 to 2020-06-30
Filed
2021-02-04
IRS object ID
202100359349301515
Schema version
2019v5.0
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2021-02-04T16:10:57-06:00ReturnTs
Tax Period End2020-06-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN135565207PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1KPMG LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1345 PARK AVENUEAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP101540102ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2019-07-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN135644916EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1THE LEUKEMIA & LYMPHOMA SOCIETYINCBusinessNameLine1Txt
FieldValueIRS element (for citing)
Business Name ControlLEUKBusinessNameControlTxt
Phone9149495213PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVEAddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonGORDON MILLER JRPersonNm
Person TitleEVP CHIEF FIN OFFICEPersonTitleTxt
Phone3125687727PhoneNum
Signature2021-02-03SignatureDt
Discuss With Paid PreparerYes (true)DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonDAVID M HIGHFILLPreparerPersonNm
PTINP01517891PTIN
Phone2127589700PhoneNum
Preparation2021-02-04PreparationDt
FieldValueIRS element (for citing)
Tax2019TaxYr
Build TS2022-09-23 18:48:47ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Principal OfficerLOUIS J DEGENNAROPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVE SUITE 200AddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$588,672,573GrossReceiptsAmt
Group Return For AffiliatesfalseGroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.LLS.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1949FormationYr
Legal Domicile StateNYLegalDomicileStateCd
Activity Or MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.ActivityOrMissionDesc
Voting Members Governing Body23VotingMembersGoverningBodyCnt
Voting Members Independent23VotingMembersIndependentCnt
Total Employee1377TotalEmployeeCnt
Total Volunteers3000000TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
PY Contributions Grants$372,750,094PYContributionsGrantsAmt
CY Contributions Grants$427,419,530CYContributionsGrantsAmt
PY Program Service Revenue$14,936,342PYProgramServiceRevenueAmt
CY Program Service Revenue$15,997,252CYProgramServiceRevenueAmt
PY Investment Income$8,619,914PYInvestmentIncomeAmt
CY Investment Income$33,847,009CYInvestmentIncomeAmt
PY Other Revenue-$85,198PYOtherRevenueAmt
CY Other Revenue$18,957,518CYOtherRevenueAmt
PY Total Revenue$396,221,152PYTotalRevenueAmt
CY Total Revenue$496,221,309CYTotalRevenueAmt
PY Grants And Similar Paid$146,416,708PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$169,606,729CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$113,204,908PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$126,383,366CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$5,823,217PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$4,373,282CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$45,035,639CYTotalFundraisingExpenseAmt
PY Other Expenses$101,876,640PYOtherExpensesAmt
CY Other Expenses$93,633,073CYOtherExpensesAmt
PY Total Expenses$367,321,473PYTotalExpensesAmt
CY Total Expenses$393,996,450CYTotalExpensesAmt
PY Revenues Less Expenses$28,899,679PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$102,224,859CYRevenuesLessExpensesAmt
Total Assets BOY$454,102,204TotalAssetsBOYAmt
Total Assets EOY$581,677,610TotalAssetsEOYAmt
Total Liabilities BOY$185,710,815TotalLiabilitiesBOYAmt
Total Liabilities EOY$215,555,172TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$268,391,389NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$366,122,438NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionOUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.MissionDesc
Significant New Program SrvcfalseSignificantNewProgramSrvcInd
Significant ChangefalseSignificantChangeInd
Expense$47,726,107ExpenseAmt
Grant$26,818,848GrantAmt
Revenue$15,997,252RevenueAmt
DescA) RESEARCH PROGRAMS WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2020, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 8 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 26.8 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. AT THE END OF 2020, THE BEAT AML TRIAL HAD ENROLLED 1,000 PATIENTS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE- EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2018, FOR THE SEVENTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FODesc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$198,424,766ExpenseAmt
Grant$142,787,881GrantAmt
DescB) PATIENT & COMMUNITY SERVICES SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER, LLS WEBSITE AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL. IN 2020, 615,299 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 12,296 FACT SHEETS WERE ORDERED. ADDITIONALLY, THERE WERE 131,924 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. EDUCATION MATERIALS ARE AVAILABLE TO DOWNLOAD OR ORDER AT WWW.LLS.ORG/BOOKLETS. MANY MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH, AND SELECT MATERIALS ARE AVAILABLE IN ADDITIONAL LANGUAGES. FINANCIAL ASSISTANCE IN 2020, A COMBINED 142,351,684 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAM (131,293,984), THE LLS SUSAN LANG PATIENT TRAVEL ASSISTANCE PROGRAM (2,667,500), THE LLS URGENT NEED PROGRAM (1,833,500), LLS PATIENT AID PROGRAM (1,722,200), AND THE COVID-19 PATIENT FINANCIAL AID PROGRAM (4,834,500). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2020, 131,293,984 WAS PROVIDED TO 22,253 PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2020, 2,667,500 WAS PROVIDED TO 5,335 PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM. URGENT NEED PROGRAM THE URGENT NEED PROGRAM WAS ESTABLISHED TO HELP PEDIATRIC AND YOUNG ADULT BLOOD CANCER PATIENTS, OR ADULT BLOOD CANCER PATIENTS ENROLLED IN CLINICAL TRIALS, WHO ARE IN ACUTE FINANCIAL NEED. THE PROGRAM PROVIDES ELIGIBLE PATIENTS ASSISTANCE FOR NON-MEDICAL EXPENSES INCLUDING RENT, MORTGAGE, LODGING, UTILITIES, CHILDCARE, ELDER CARE, FOOD, TRANSPORTATION, CAR REPAIR, CAR INSURANCE, PHONE SERVICE, AND ACUTE DENTAL WORK RELATED TO TREATMENT. IN 2020, 1,833,500 WAS PROVIDED TO 3,667 PATIENTS THROUGH THE LLS URGENT NEED PROGRAM. PATIENT AID PROGRAM THE PATIENT AID PROGRAM PROVIDES FINANCIAL ASSISTANCE TO BLOOD CANCER PATIENTS. ELIGIBLE PATIENTS WILL RECEIVE A ONE-TIME 100 STIPEND TO HELP OFFSET EXPENSES. IN 2020, 1,722,200 WAS PROVIDED TO 17,222 PATIENTS THROUGH THE LLS PATIENT AID PROGRAM. LLS COVID-19 PATIENT FINANCIAL AID PROGRAM LLS ESTABLISHED THE LLS COVID-19 PATIENT FINANCIAL AID PROGRAM TO HELP ELIGIBLE BLOOD CANCER PATIENTS EXPERIENCING FINANCIAL HARDSHIP DUE TO THE PANDEMIC. ELIGIBLE PATIENTS WILL RECEIVED A ONE-TIME 250 STIPEND TO HELP OFFSET EXPENSES. IN 2020, 4,834,500 WAS PROVIDED TO 19,338 PATIENTS THROUGH THE COVID-19 PATIENT FINANCIAL AID PROGRAM. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY EDUCATION & SERVICES STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL; THIS YEAR, MOST WERE IN-PERSON BUT ONE WAS VIRTUAL DUE TO COVID-19. IN 2020, EIGHT BCC CONFERENCES WERE HELD WITH 4,065 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016 TO HONOR THE MEMORY OF MICHAEL GARIL, WHO WAS DIAGNOSED WITH ALL IN 1974 AT THE AGE OF SEVEN. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2020, THERE WERE APPROXIMATELY 75,472 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2020 LLS SUPPORTED OR HOSTED 127 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS ALSO HOSTED 7 ONLINE NATIONAL CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2020, 5,246 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS AND CAREGIVERS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT/CAREGIVER- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE PATIENT/CAREGIVER TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,700 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2020.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$44,287,931ExpenseAmt
DescC) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE HIGHLY TRAINED ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS MAY ALSO REFER PATIENTS AND CAREGIVERS TO A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER (CTSC). THE NURSES IN THE CTSC HAVE EXPERTISE IN THE BLOOD CANCERS AND PROVIDE PATIENTS AND THEIR CAREGIVERS WITH COMPREHENSIVE NAVIGATION TO FIND AND ENROLL IN AN APPROPRIATE CLINICAL TRIAL. AS PART OF THIS PROCESS, THE NURSES WORK CLOSELY WITH INFORMATION SPECIALISTS TO ADDRESS RESOURCE BARRIERS TO CLINICAL TRIAL ENROLLMENT. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2020: - 25,202 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 14,580 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -779 PATIENTS WORKED WITH A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 20% OF PATIENTS ASSISTED ENROLLED ON A CLINICAL TRIAL. LLS OFFERS PATIENTS AND CAREGIVERS FREE ONE-ON-ONE PHONE AND EMAIL CONSULTATIONS WITH A REGISTERED DIETITIAN WITH EXPERTISE IN ONCOLOGY NUTRITION. THIS SERVICE IS AVAILABLE TO ALL CANCER PATIENTS AND THEIR CAREGIVERS. IN FY 20 NEARLY 1,000 CONSULTATIONS WERE PROVIDED. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING FINANCIAL ASSISTANCE, INFORMATION SPECIALISTS, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH (AND ADDITIONAL LANGUAGES FOR SELECT MATERIALS), PERSONALIZED CLINICAL TRIAL NAVIGATION BY A REGISTERED NURSE, PERSONALIZED NUTRITION CONSULTATIONS BY A REGISTERED DIETICIAN AND CONTINUING EDUCATION PROGRAMS FOR HEALTHCARE PROFESSIONALS. NATIONAL TELEPHONE/WEB EDUCATION PROGRAMS LLS CONDUCTS TELEPHONE-WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES AS WELL AS SURVIVORSHIP ISSUES. PROGRAM PARTICIPANTS ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS DELIVERED BY WORLD RENOWNED CLINICAL EXPERTS. UPCOMING AND ARCHIVED PROGRAMS ARE POSTED AT WWW.LLS.ORG/WEBCASTS. IN FY 2020: -LLS CONDUCTED 16 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 12,713 PARTICIPANTS -THERE WERE 51,125 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 25,367 VIRTUAL LECTURE VIEWS; 21,427 PODCAST DOWNLOADS; AND 60,234 VIDEO VIEWS.Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

FieldValueIRS element (for citing)
Expense$15,553,960ExpenseAmt
DescD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2020: -LLS PROVIDED 9 CME/CE-GRANTING IN-PERSON EDUCATIONAL PROGRAMS, WITH 1,407 HEALTHCARE PROFESSIONALS IN ATTENDANCE. --THERE WERE 36,338 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 22,394 VIRTUAL LECTURE VIEWS AND 11,433 PODCAST DOWNLOADS.Desc
FieldValueIRS element (for citing)
Total Other Prog Srvc Expense$15,553,960TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses$305,992,764TotalProgramServiceExpensesAmt
Described In Section501c3Yes (true)DescribedInSection501c3Ind
Schedule B RequiredYes (true)ScheduleBRequiredInd
Political Campaign ActyfalsePoliticalCampaignActyInd
Lobbying ActivitiesYes (true)LobbyingActivitiesInd
Subject To Proxy TaxfalseSubjectToProxyTaxInd
Donor Advised FundfalseDonorAdvisedFundInd
Conservation EasementsfalseConservationEasementsInd
Collections Of ArtYes (true)CollectionsOfArtInd
Credit CounselingfalseCreditCounselingInd
Donor Rstr Or Quasi EndowmentsYes (true)DonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentYes (true)ReportLandBuildingEquipmentInd
Report Investments Other SecfalseReportInvestmentsOtherSecInd
Report Program Related InvstfalseReportProgramRelatedInvstInd
Report Other AssetsfalseReportOtherAssetsInd
Report Other LiabilitiesfalseReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (true)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtfalseIndependentAuditFinclStmtInd
Consolidated Audit Fincl StmtYes (true)ConsolidatedAuditFinclStmtInd
School OperatingfalseSchoolOperatingInd
Foreign OfficeYes (true)ForeignOfficeInd
Foreign ActivitiesYes (true)ForeignActivitiesInd
More Than5000 K To OrgYes (true)MoreThan5000KToOrgInd
More Than5000 K To IndividualsfalseMoreThan5000KToIndividualsInd
Professional FundraisingYes (true)ProfessionalFundraisingInd
Fundraising ActivitiesYes (true)FundraisingActivitiesInd
Gaming ActivitiesYes (true)GamingActivitiesInd
Operate HospitalfalseOperateHospitalInd
Grants To OrganizationsYes (true)GrantsToOrganizationsInd
Grants To IndividualsYes (true)GrantsToIndividualsInd
Schedule J RequiredYes (true)ScheduleJRequiredInd
Tax Exempt BondsfalseTaxExemptBondsInd
Engaged In Excess Benefit TransfalseEngagedInExcessBenefitTransInd
PY Excess Benefit TransfalsePYExcessBenefitTransInd
Loan OutstandingfalseLoanOutstandingInd
Grant To Related PersonfalseGrantToRelatedPersonInd
Business Rln With Org MemfalseBusinessRlnWithOrgMemInd
Business Rln With Fam MemfalseBusinessRlnWithFamMemInd
Business Rln With35 Ctrl EntfalseBusinessRlnWith35CtrlEntInd
Deductible Non Cash ContriYes (true)DeductibleNonCashContriInd
Deductible Art ContributionfalseDeductibleArtContributionInd
Terminate OperationsfalseTerminateOperationsInd
Partial LiquidationfalsePartialLiquidationInd
Disregarded EntityYes (true)DisregardedEntityInd
Related EntityYes (true)RelatedEntityInd
Related Organization Ctrl EntYes (true)RelatedOrganizationCtrlEntInd
Transaction With Control EntYes (true)TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd OrgfalseTrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted PrtshpfalseActivitiesConductedPrtshpInd
Schedule O RequiredYes (true)ScheduleORequiredInd
IRP Document964IRPDocumentCnt
IRP Document W2 G3IRPDocumentW2GCnt
Backup Wthld ComplianceYes (true)BackupWthldComplianceInd
Employee1377EmployeeCnt
Employment Tax Returns FiledYes (true)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over LimitfalseUnrelatedBusIncmOverLimitInd
Foreign Financial AccountYes (true)ForeignFinancialAccountInd
Foreign CountryCAForeignCountryCd
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTransInd
Taxable Party NotificationfalseTaxablePartyNotificationInd
Nondeductible ContributionsfalseNondeductibleContributionsInd
Quid Pro Quo ContributionsYes (true)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (true)QuidProQuoContriDisclInd
Form8282 Property Disposed OffalseForm8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft CntrctfalseRcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft CntrctfalsePayPremiumsPrsnlBnftCntrctInd
Indoor Tanning ServicesfalseIndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht PymtfalseSubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst IncfalseSubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members23GoverningBodyVotingMembersCnt
Independent Voting Member23IndependentVotingMemberCnt
Family Or Business RlnfalseFamilyOrBusinessRlnInd
Delegation Of Mgmt DutiesfalseDelegationOfMgmtDutiesInd
Change To Org DocumentsfalseChangeToOrgDocumentsInd
Material Diversion Or MisusefalseMaterialDiversionOrMisuseInd
Members Or StockholdersfalseMembersOrStockholdersInd
Election Of Board MembersfalseElectionOfBoardMembersInd
Decisions Subject To ApprovafalseDecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (true)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (true)MinutesOfCommitteesInd
Officer Mailing AddressfalseOfficerMailingAddressInd
Local ChaptersYes (true)LocalChaptersInd
Policies Reference ChaptersYes (true)PoliciesReferenceChaptersInd
Form990 Provided To Gvrn BodyYes (true)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (true)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (true)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (true)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (true)WhistleblowerPolicyInd
Document Retention PolicyYes (true)DocumentRetentionPolicyInd
Compensation Process CEOYes (true)CompensationProcessCEOInd
Compensation Process OtherYes (true)CompensationProcessOtherInd
Investment In Joint VenturefalseInvestmentInJointVentureInd
States Where Copy Of Return Is FldAKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldAZStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldDCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldHIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldIDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldINStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldLAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNMStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPRStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldRIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
Own WebsiteYes (X)OwnWebsiteInd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

FieldValueIRS element (for citing)
PersonGORDON MILLER JRPersonNm
Phone9148218935PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVEAddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (36 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtHighest Compensated EmployeeHighestCompensatedEmployeeIndFormer Ofcr Director TrusteeFormerOfcrDirectorTrusteeIndIndividual Trustee Or DirectorIndividualTrusteeOrDirectorInd
LOUIS J DEGENNARO
PRESIDENT &40.001.00Yes (X)$782,431$0$43,454
GWEN NICHOLS
EVP CHIEF ME40.001.00Yes (X)$501,371$0$40,169
KATHY GRIESENBECK
EVP CHIEF RE40.00$384,569$0$38,373Yes (X)
LEE M GREENBERGER
SVP CHIEF SC40.00$373,664$0$49,055Yes (X)
VANESSA WHITE
SVP CHIEF AD40.00$391,796$0$20,854Yes (X)
COKER POWELL
EVP PROD CAM40.00$358,654$0$49,200Yes (X)
ROSEMARIE ALOFFREDO - END 3312019
CHIEF FIN OF40.00$385,700$0$10,231Yes (X)
THOMAS OSGOOD
EVP CHIEF HU40.00$348,316$0$30,696Yes (X)
GORDON MILLER JR
EVP CHIEF FI40.001.00Yes (X)$331,908$0$39,930
ROBERT BECK - END 7519
EVP CHIEF OP40.001.00Yes (X)$350,503$0$3,321
HARRY MOSELEY - END 1152020
BOD MEMBER4.00$0$0$0Yes (X)
MICHELE CAMERON - START 7119
BOD MEMBER4.00$0$0$0Yes (X)
JAMES PALMER - START 712019
BOD MEMBER4.00$0$0$0Yes (X)
SAMUEL EBERTS - END 872019
BOD MEMBER4.00$0$0$0Yes (X)
KEITH WHITE - END 9302019
BOD MEMBER4.00$0$0$0Yes (X)
WILLIAM G BEHNKE
BOD MEMBER4.00$0$0$0Yes (X)
JORGE L BENITEZ
CHAIRMAN4.00Yes (X)$0$0$0Yes (X)
PETER B BROCK
BOD MEMBER4.00$0$0$0Yes (X)
A DANA CALLOW
BOD MEMBER4.00$0$0$0Yes (X)
CASEY CUNNINGHAM
BOD MEMBER4.00$0$0$0Yes (X)
CHRISTOPHER FLOWERS
BOD MEMBER4.00$0$0$0Yes (X)
JANICE GABRILOVE
BOD MEMBER4.00$0$0$0Yes (X)
BERNARD H GARIL
BOD MEMBER4.00$0$0$0Yes (X)
JOHN GREENE
BOD MEMBER4.00$0$0$0Yes (X)
FRANCIE HELLER
BOD MEMBER4.00$0$0$0Yes (X)
RALPH E LAWSON
SECRETARY/TR4.00Yes (X)$0$0$0Yes (X)
RENZO CANETTA MD
BOD MEMBER4.00$0$0$0Yes (X)
KATHLEEN MERIWETHER
AT LARGE4.00Yes (X)$0$0$0Yes (X)
RUBEN MESA
BOD MEMBER4.00$0$0$0Yes (X)
LYNNE O'BRIEN
BOD MEMBER4.00$0$0$0Yes (X)
MARLA PERSKY
BOD MEMBER4.00$0$0$0Yes (X)
MICHELLE LE BEAU PHD
BOD MEMBER4.00$0$0$0Yes (X)
ROBERT ROSEN
BOD MEMBER4.00$0$0$0Yes (X)
STEVEN T ROSEN
BOD MEMBER4.00$0$0$0Yes (X)
JEFF SACHS
BOD MEMBER4.00$0$0$0Yes (X)
BART SICHEL
VICE CHAIR4.00Yes (X)$0$0$0Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$4,208,912TotalReportableCompFromOrgAmt
Total Other Compensation$325,283TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K231IndivRcvdGreaterThan100KCnt
Former Ofcr Employees ListedYes (true)FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (true)TotalCompGreaterThan150KInd
Compensation From Other SrcsfalseCompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1TxtCityContractorAddress/USAddress/CityNmState AbbreviationContractorAddress/USAddress/StateAbbreviationCdZIPContractorAddress/USAddress/ZIPCdServicesServicesDescCompensationCompensationAmt
SYNEOS HEALTH LLC
75 REMITTANCE DRIVE SUITE 3160CHICAGOIL606753160CLINICAL TRIAL$8,516,649
PATIENT ADVOCACY FOUNDATION
421 BUTLER FARM RDHAMPTONVA23666PAT ASSIST PROC$5,486,159
TARGETCW
9475 CHESEPAKE DRIVESAN DIEGOCA92123TEMP STAFFING$4,508,661
RESOURCE ONE
2900 EAST APACHE STREETTULSAOK74110DIRECT MARKETIN$4,249,038
MERKLE
29432 NETWORK PLACECHICAGOIL606731294MARKETING$3,331,159
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K147CntrctRcvdGreaterThan100KCnt
Info In Schedule O Part VIIIYes (X)InfoInScheduleOPartVIIIInd
Federated Campaigns$809,036FederatedCampaignsAmt
Fundraising$159,181,536FundraisingAmt
All Other Contributions$267,428,958AllOtherContributionsAmt
Noncash Contributions$2,611,447NoncashContributionsAmt
Total Contributions$427,419,530TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

FieldValueIRS element (for citing)
DescSERVICE REVENUEDesc
Business810000BusinessCd
Total Revenue Column$15,997,252TotalRevenueColumnAmt
Related Or Exempt Func Income$15,997,252RelatedOrExemptFuncIncomeAmt
FieldValueIRS element (for citing)
Total Program Service Revenue$15,997,252TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$7,516,159TotalRevenueColumnAmt
Exclusion$7,516,159ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$21,565,914TotalRevenueColumnAmt
Exclusion$21,565,914ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$99,668,300SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$73,337,450SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$26,330,850SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$26,330,850TotalRevenueColumnAmt
Exclusion$26,330,850ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$16,337,089FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$159,181,536ContriRptFundraisingEventAmt
Fundraising Direct Expenses$18,862,365FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column-$2,525,276TotalRevenueColumnAmt
Exclusion-$2,525,276ExclusionAmt
FieldValueIRS element (for citing)
Gaming Gross Income$168,329GamingGrossIncomeAmt
Gaming Direct Expenses$251,449GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

FieldValueIRS element (for citing)
Total Revenue Column-$83,120TotalRevenueColumnAmt
Exclusion-$83,120ExclusionAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$496,221,309TotalRevenueColumnAmt
Related Or Exempt Func Income$15,997,252RelatedOrExemptFuncIncomeAmt
Exclusion$52,804,527ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$22,515,926TotalAmt
Program Services$22,515,926ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

FieldValueIRS element (for citing)
Total$142,787,883TotalAmt
Program Services$142,787,883ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$4,302,920TotalAmt
Program Services$4,302,920ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$1,869,067TotalAmt
Program Services$663,635ProgramServicesAmt
Management And General$946,204ManagementAndGeneralAmt
Fundraising$259,228FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$102,862,095TotalAmt
Program Services$62,890,873ProgramServicesAmt
Management And General$20,824,371ManagementAndGeneralAmt
Fundraising$19,146,851FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$2,409,014TotalAmt
Program Services$1,409,908ProgramServicesAmt
Management And General$560,153ManagementAndGeneralAmt
Fundraising$438,953FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$12,379,429TotalAmt
Program Services$7,271,349ProgramServicesAmt
Management And General$2,840,520ManagementAndGeneralAmt
Fundraising$2,267,560FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$6,863,761TotalAmt
Program Services$4,017,108ProgramServicesAmt
Management And General$1,595,988ManagementAndGeneralAmt
Fundraising$1,250,665FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

FieldValueIRS element (for citing)
Total$1,504,262TotalAmt
Program Services$902,557ProgramServicesAmt
Management And General$406,151ManagementAndGeneralAmt
Fundraising$195,554FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

FieldValueIRS element (for citing)
Total$439,394TotalAmt
Management And General$439,394ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

FieldValueIRS element (for citing)
Total$1,058,015TotalAmt
Program Services$1,058,015ProgramServicesAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$4,373,282TotalAmt
Fundraising$4,373,282FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$559,186TotalAmt
Program Services$437,129ProgramServicesAmt
Management And General$58,453ManagementAndGeneralAmt
Fundraising$63,604FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$27,300,414TotalAmt
Program Services$19,104,039ProgramServicesAmt
Management And General$4,585,419ManagementAndGeneralAmt
Fundraising$3,610,956FundraisingAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$9,105,977TotalAmt
Program Services$4,911,163ProgramServicesAmt
Management And General$947,263ManagementAndGeneralAmt
Fundraising$3,247,551FundraisingAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$17,573,037TotalAmt
Program Services$10,237,589ProgramServicesAmt
Management And General$1,390,803ManagementAndGeneralAmt
Fundraising$5,944,645FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$2,572,277TotalAmt
Program Services$193,950ProgramServicesAmt
Management And General$1,910,687ManagementAndGeneralAmt
Fundraising$467,640FundraisingAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$9,468,572TotalAmt
Program Services$6,474,775ProgramServicesAmt
Management And General$1,198,591ManagementAndGeneralAmt
Fundraising$1,795,206FundraisingAmt

Travel TravelGrp

FieldValueIRS element (for citing)
Total$7,093,063TotalAmt
Program Services$4,836,436ProgramServicesAmt
Management And General$1,061,275ManagementAndGeneralAmt
Fundraising$1,195,352FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$3,603,144TotalAmt
Program Services$345,543ProgramServicesAmt
Management And General$3,108,662ManagementAndGeneralAmt
Fundraising$148,939FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$840,829TotalAmt
Program Services$16,685ProgramServicesAmt
Management And General$824,144ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDescTotalTotalAmtProgram ServicesProgramServicesAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmt
RESEARCH AND DEVELOPMENT$8,878,112$8,878,112
MISCELLANEOUS$3,636,791$2,737,169$269,969$629,653

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$393,996,450TotalAmt
Program Services$305,992,764ProgramServicesAmt
Management And General$42,968,047ManagementAndGeneralAmt
Fundraising$45,035,639FundraisingAmt
FieldValueIRS element (for citing)
Joint CostsYes (X)JointCostsInd

Total Joint Costs TotalJointCostsGrp

FieldValueIRS element (for citing)
Total$16,991,219TotalAmt
Program Services$9,899,510ProgramServicesAmt
Fundraising$7,091,709FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$22,082,281BOYAmt
EOY$27,772,961EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

FieldValueIRS element (for citing)
BOY$239,148,833BOYAmt
EOY$363,331,593EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$15,172,625BOYAmt
EOY$24,021,989EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$4,318,740BOYAmt
EOY$3,815,548EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$53,740,279LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$44,394,387LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$9,045,769BOYAmt
EOY$9,345,892EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$148,509,455BOYAmt
EOY$138,900,813EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

FieldValueIRS element (for citing)
BOY$10,061,475BOYAmt
EOY$10,426,610EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

FieldValueIRS element (for citing)
BOY$5,763,026BOYAmt
EOY$4,062,204EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$454,102,204BOYAmt
EOY$581,677,610EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$27,935,486BOYAmt
EOY$23,457,200EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$144,560,351BOYAmt
EOY$179,469,755EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$13,214,978BOYAmt
EOY$12,628,217EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$185,710,815BOYAmt
EOY$215,555,172EOYAmt
FieldValueIRS element (for citing)
Organization Follows FASB117Yes (X)OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$174,200,077BOYAmt
EOY$249,719,310EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$94,191,312BOYAmt
EOY$116,403,128EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$268,391,389BOYAmt
EOY$366,122,438EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$454,102,204BOYAmt
EOY$581,677,610EOYAmt
FieldValueIRS element (for citing)
Info In Schedule O Part XIYes (X)InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss$102,224,859ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst-$4,494,255NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets$445OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or ReviewfalseAccountantCompileOrReviewInd
FS AuditedYes (true)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Consolidated Basis Fincl StmtYes (X)ConsolidatedBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (true)AuditCommitteeInd
Federal Grant Audit RequiredfalseFederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$285,638,088CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$314,912,814CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$419,570,497CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$372,750,094CurrentTaxYearMinus1YearAmt
Current Tax Year$427,419,530CurrentTaxYearAmt
Total$1,820,291,023TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$285,638,088CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$314,912,814CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$419,570,497CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$372,750,094CurrentTaxYearMinus1YearAmt
Current Tax Year$427,419,530CurrentTaxYearAmt
Total$1,820,291,023TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$384,987,491SubstantialContributorsTotAmt
Public Support Total170$1,435,303,532PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,565,846CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$7,018,822CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$8,235,985CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$11,830,162CurrentTaxYearMinus1YearAmt
Current Tax Year$29,082,073CurrentTaxYearAmt
Total$57,732,888TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$19,529CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$25,439,044CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$70,000CurrentTaxYearMinus2YearsAmt
Total$25,528,573TotalAmt
FieldValueIRS element (for citing)
Total Support$1,903,552,484TotalSupportAmt
Gross Receipts Rltd Activities$104,010,633GrossReceiptsRltdActivitiesAmt
Public Support CY1700.75400PublicSupportCY170Pct
Public Support PY1700.80160PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferencePART II, LINE 10FormAndLineReferenceDesc
ExplanationOTHER MISC. REVENUE (YR 2015-2017) 208,377 TAP CONTRACTUAL RETURN (YR 2016) 25,320,196ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule C IRS990ScheduleC

FieldValueIRS element (for citing)
VolunteersYes (true)VolunteersInd
Paid Staff Or ManagementYes (true)PaidStaffOrManagementInd
Media AdvertisementsYes (true)MediaAdvertisementsInd
Media Advertisements$40,413MediaAdvertisementsAmt
Mailings MembersfalseMailingsMembersInd
Publications Or BroadcastYes (true)PublicationsOrBroadcastInd
Publications Or Broadcast$213,677PublicationsOrBroadcastAmt
Grants Other OrganizationsfalseGrantsOtherOrganizationsInd
Direct Contact LegislatorsYes (true)DirectContactLegislatorsInd
Direct Contact Legislators$382,656DirectContactLegislatorsAmt
Rallies DemonstrationsYes (true)RalliesDemonstrationsInd
Rallies Demonstrations$202,660RalliesDemonstrationsAmt
Other ActivitiesYes (true)OtherActivitiesInd
Other Activities$834,507OtherActivitiesAmt
Total Lobbying Expenditures$1,673,913TotalLobbyingExpendituresAmt
Not Described Section501c3falseNotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE C, PART II-B, LINE 1FormAndLineReferenceDesc
ExplanationLLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL, AMERICAN CHILDHOOD CANCER ORGANIZATION, PUBLIC AFFAIRS COUNCIL, PATIENT QUALITY OF LIFE COALITION, DEFENSE HEALTH RESEARCH CONSORTIUM, AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. LLS PARTNERS WITH LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS'S POLICY AGENDA.ExplanationTxt

Schedule D IRS990ScheduleD

FieldValueIRS element (for citing)
Collection Used Pub ExhibitionYes (X)CollectionUsedPubExhibitionInd
Solicited Assets SalefalseSolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,168,319BeginningYearBalanceAmt
Investment Earnings Or Losses-$8,812InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$246,718GrantsOrScholarshipsAmt
Administrative Expenses-$9,998AdministrativeExpensesAmt
End Year Balance$5,902,791EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,192,807BeginningYearBalanceAmt
Investment Earnings Or Losses$292,934InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$304,999GrantsOrScholarshipsAmt
Administrative Expenses-$12,423AdministrativeExpensesAmt
End Year Balance$6,168,319EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$5,897,377BeginningYearBalanceAmt
Contributions$200ContributionsAmt
Investment Earnings Or Losses$546,324InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$237,896GrantsOrScholarshipsAmt
Administrative Expenses-$13,198AdministrativeExpensesAmt
End Year Balance$6,192,807EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,027,967BeginningYearBalanceAmt
Contributions$5,200ContributionsAmt
Investment Earnings Or Losses$119,369InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$240,000GrantsOrScholarshipsAmt
Administrative Expenses-$15,159AdministrativeExpensesAmt
End Year Balance$5,897,377EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

FieldValueIRS element (for citing)
Beginning Year Balance$6,115,645BeginningYearBalanceAmt
Contributions$45,095ContributionsAmt
Investment Earnings Or Losses$116,288InvestmentEarningsOrLossesAmt
Grants Or Scholarships-$240,000GrantsOrScholarshipsAmt
Administrative Expenses-$9,060AdministrativeExpensesAmt
End Year Balance$6,027,967EndYearBalanceAmt
FieldValueIRS element (for citing)
Prmnnt Endowment Balance EOY0.48230PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY0.51770TermEndowmentBalanceEOYPct
Endowments Held Unrelated OrgfalseEndowmentsHeldUnrelatedOrgInd
Endowments Held Related OrgfalseEndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$2,667,193OtherCostOrOtherBasisAmt
Depreciation$1,741,478DepreciationAmt
Book Value$925,715BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$46,601,764OtherCostOrOtherBasisAmt
Depreciation$38,977,404DepreciationAmt
Book Value$7,624,360BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$4,471,322OtherCostOrOtherBasisAmt
Depreciation$3,675,505DepreciationAmt
Book Value$795,817BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$9,345,892TotalBookValueLandBuildingsAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$508,252,673TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst-$4,494,255NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$7,993,521DonatedServicesAndUseFcltsAmt
Other Revenue$9,091,284OtherRevenueAmt
Revenue Not Reported$12,590,550RevenueNotReportedAmt
Revenue Subtotal$495,662,123RevenueSubtotalAmt
Investment Expenses Not Incld$559,186InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt$559,186RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$496,221,309TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$408,790,422TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$7,993,521DonatedServicesUseFcltsAmt
Other Expenses Included$7,054,447OtherExpensesIncludedAmt
Expenses Not Reported$15,047,968ExpensesNotReportedAmt
Expenses Subtotal$393,742,454ExpensesSubtotalAmt
Investment Expenses Not Incld2$559,186InvestmentExpensesNotIncld2Amt
Other Expenses Not Included-$305,190OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt$253,996ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$393,996,450TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (6 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE D, PAGE 2, PART III, LINE 4THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
SCHEDULE D, PAGE 2, PART V, LINE 4LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
SCHEDULE D, PAGE 3, PART XLLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDING, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUM CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSMEENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NO ENTITIES THAT RECOGNIZED ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2020 AND 2019.
SCHEDULE D, PAGE 4, PART XI, LINE 2DLLS CANADA REVENUE 9,091,284
SCHEDULE D, PAGE 4, PART XII, LINE 2DLLS CANADA EXPENSES 7,054,447
SCHEDULE D, PAGE 4, PART XII, LINE 4BLLS CANADA FOREIGN CURRENCY ADJ -305,190

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (6 entries)

RegionRegionTxtOfficesOfficesCntType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmt
NORTH AMERICA3RESEARCH FUNDINGRESEARCH GRANTS$580,000
EUROPE8RESEARCH FUNDINGRESEARCH GRANTS$1,811,818
EUROPE1INVESTMENTSINVESTMENTS$258,102
CENTRAL AMERICA & CARIBBEAN6INVESTMENTSINVESTMENTS$9,607,316
MIDDLE EAST & NORTH AFRICA1RESEARCH FUNDINGRESEARCH GRANTS$90,000
EAST ASIA & THE PACIFIC4RESEARCH FUNDINGRESEARCH GRANTS$1,821,102
FieldValueIRS element (for citing)
Subtotal Offices23SubtotalOfficesCnt
Total Office23TotalOfficeCnt
Subtotal Spent$14,168,338SubtotalSpentAmt
Total Spent$14,168,338TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (12 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxtValuation Method UsedValuationMethodUsedDesc
MIDDLE EAST & NORTHRESEARCH GRANT$90,000WIREACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$1,200,000WIREACCRUAL
NORTH AMERICARESEARCH GRANT$370,000WIREACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$200,000WIREACCRUAL
EAST ASIA & PACIFICRESEARCH GRANT$421,102WIREACCRUAL
EUROPETHERAPY ACCELERATED$950,000WIREFMV
NORTH AMERICARESEARCH GRANT$105,000WIREACCRUAL
EUROPERESEARCH GRANT$70,000WIREACCRUAL
NORTH AMERICARESEARCH GRANT$105,000WIREACCRUAL
EUROPERESEARCH GRANT$69,973WIREACCRUAL
EUROPETHERAPY ACCELERATED$670,998WIREFMV
EUROPERESEARCH GRANT$50,847WIREACCRUAL
FieldValueIRS element (for citing)
Total Other Org12TotalOtherOrgCnt
Transfer To Foreign CorpYes (true)TransferToForeignCorpInd
Interest In Foreign TrustfalseInterestInForeignTrustInd
Foreign Corp OwnershipYes (true)ForeignCorpOwnershipInd
Passive Foreign Investmest CoYes (true)PassiveForeignInvestmestCoInd
Foreign PartnershipfalseForeignPartnershipInd
Boycott CountriesfalseBoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE F, PAGE 1, PART I, LINE 2FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS.
SCHEDULE F, PAGE 1, PART I, LINE 3NORTH AMERICA 580,000 0 EUROPE 1,811,818 0 EUROPE 258,102 0 CENTRAL AMERICA & CARIBBEAN 9,607,316 0 MIDDLE EAST & NORTH AFRICA 90,000 0 EAST ASIA & THE PACIFIC 1,821,102 0

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsYes (X)MailSolicitationsInd
Email SolicitationsYes (X)EmailSolicitationsInd
Phone SolicitationsYes (X)PhoneSolicitationsInd
In Person SolicitationsYes (X)InPersonSolicitationsInd
Solicitation Of Non Govt GrantsYes (X)SolicitationOfNonGovtGrantsInd
Special Fundraising EventsYes (X)SpecialFundraisingEventsInd
Agrmt Prof Fundraising ActyYes (true)AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (3 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdActivityActivityTxtFundraiser Control Of FundsFundraiserControlOfFundsIndGross ReceiptsGrossReceiptsAmtRetained By ContractorRetainedByContractorAmtNet To OrganizationNetToOrganizationAmt
COINSTAR
1800 114TH AVENUE SEBELLEVUEWA98004COIN COLLEfalse$3,668,380$3,263,971$404,409
THOMPSON HABIB & DENISON
80 HAYDEN AVENUE SUITE 300LEXINGTONMA02421DIRECT MAIfalse$632,452-$632,452
THE HERITAGE COMPANY INC
PO BOX 16325LITTLE ROCKAR722316325DIRECT MAIfalse$85,512-$85,512
FieldValueIRS element (for citing)
Total Gross Receipts$3,668,380TotalGrossReceiptsAmt
Total Retained By Contractors$3,981,935TotalRetainedByContractorsAmt
Total Net To Organization-$313,555TotalNetToOrganizationAmt
All StatesAll StatesAllStatesCd

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Event1SEATTLE BIG CLIEvent1Nm
Gross Receipts Event1$2,800,011GrossReceiptsEvent1Amt
Charitable Contri Event1$2,631,781CharitableContriEvent1Amt
Gross Revenue Event1$168,230GrossRevenueEvent1Amt
Non Cash Prizes Event1$151,519NonCashPrizesEvent1Amt
Rent Facility Costs Event1$16,468RentFacilityCostsEvent1Amt
Food And Beverage Event1$242FoodAndBeverageEvent1Amt
Other Direct Expenses Event1$136OtherDirectExpensesEvent1Amt
Event2STUDENT OF THEEvent2Nm
Gross Receipts Event2$2,610,082GrossReceiptsEvent2Amt
Charitable Contri Event2$2,324,394CharitableContriEvent2Amt
Gross Revenue Event2$285,688GrossRevenueEvent2Amt
Non Cash Prizes Event2$22,088NonCashPrizesEvent2Amt
Rent Facility Costs Event2$148,578RentFacilityCostsEvent2Amt
Food And Beverage Event2$115,967FoodAndBeverageEvent2Amt
Other Direct Expenses Event2$4,333OtherDirectExpensesEvent2Amt
Other Events Total466OtherEventsTotalCnt
Gross Receipts Other Events$170,108,532GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$154,225,361CharitableContriOtherEventsAmt
Gross Revenue Other Events$15,883,171GrossRevenueOtherEventsAmt
Non Cash Prizes Other Events$4,837,653NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events$8,257,005RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events$1,993,687FoodAndBeverageOtherEventsAmt
Entertainment Other Events$868,637EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events$2,446,052OthDirectExpnssOtherEventsAmt
Gross Receipts Total$175,518,625GrossReceiptsTotalAmt
Charitable Contributions Tot$159,181,536CharitableContributionsTotAmt
Gross Revenue Total Events$16,337,089GrossRevenueTotalEventsAmt
Non Cash Prizes Total Events$5,011,260NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events$8,422,051RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events$2,109,896FoodAndBeverageTotalEventsAmt
Entertainment Total Events$868,637EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events$2,450,521OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$18,862,365DirectExpenseSummaryEventsAmt
Net Income Summary-$2,525,276NetIncomeSummaryAmt

Gaming Information GamingInformationGrp

FieldValueIRS element (for citing)
Volunteer Labor BingofalseVolunteerLaborBingoInd
Volunteer Labor Pull TabsfalseVolunteerLaborPullTabsInd
Gross Revenue Other Gaming$168,329GrossRevenueOtherGamingAmt
Cash Prizes Other Gaming$6,182CashPrizesOtherGamingAmt
Non Cash Prizes Other Gaming$83,205NonCashPrizesOtherGamingAmt
Oth Direct Expnss Other Gaming$162,062OthDirectExpnssOtherGamingAmt
Volunteer Labor Other GamingYes (true)VolunteerLaborOtherGamingInd
Volunteer Labor Other Gaming0.23000VolunteerLaborOtherGamingPct
Gross Revenue Total Gaming$168,329GrossRevenueTotalGamingAmt
Cash Prizes Total Gaming$6,182CashPrizesTotalGamingAmt
Non Cash Prizes Total Gaming$83,205NonCashPrizesTotalGamingAmt
Oth Direct Expnss Total Gaming$162,062OthDirectExpnssTotalGamingAmt
Direct Expense Summary Gaming$251,449DirectExpenseSummaryGamingAmt
Net Gaming Income Summary-$83,120NetGamingIncomeSummaryAmt
FieldValueIRS element (for citing)
States Where Gaming ConductedCTStatesWhereGamingConductedCd
States Where Gaming ConductedMIStatesWhereGamingConductedCd
States Where Gaming ConductedNJStatesWhereGamingConductedCd
States Where Gaming ConductedNVStatesWhereGamingConductedCd
States Where Gaming ConductedNYStatesWhereGamingConductedCd
States Where Gaming ConductedPAStatesWhereGamingConductedCd
States Where Gaming ConductedTXStatesWhereGamingConductedCd
States Where Gaming ConductedUTStatesWhereGamingConductedCd
LicensedYes (true)LicensedInd
License Suspended EtcfalseLicenseSuspendedEtcInd
Gaming With NonmembersfalseGamingWithNonmembersInd
Member Of Other EntityfalseMemberOfOtherEntityInd
Gaming Own Facility0.19000GamingOwnFacilityPct
Gaming Other Facility0.81000GamingOtherFacilityPct
Individual With BooksGORDON MILLER JRIndividualWithBooksNm

Persons With Books US Address PersonsWithBooksUSAddress

FieldValueIRS element (for citing)
Address Line13 INTERNATIONAL DRIVE SUITE 200AddressLine1Txt
CityRYE BROOKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10573ZIPCd
FieldValueIRS element (for citing)
Cntrct With3rd Prty For Game RevfalseCntrctWith3rdPrtyForGameRevInd
Gaming Manager PersonSEE SCHEDULE G PART IVGamingManagerPersonNm
Charitable Distribution RqrfalseCharitableDistributionRqrInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE G, PAGE 2, PART III, LINE 9UTAH
SCHEDULE G, PART IVSCHEDULE G PART I, LINE 2B LLS USED THOMSON, HABIB & DENISON AND THE HERITAGE COMPANY FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. LLS USED COINSTAR FOR ITS COIN COLLECTION DURING. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF FAIR MARKET VALUE BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 16 THE LEUKEMIA & LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC REGIONAL STAFF.

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (true)GrantRecordsMaintainedInd

Recipient Table RecipientTable (74 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtValuation Method UsedValuationMethodUsedDescPurpose Of GrantPurposeOfGrantTxtAddress Line2USAddress/AddressLine2Txt
ALBERT EINSTEIN COLLEGE OF MEDICIN
1300 MORRIS PARK AVE BELFER 1108BRONXNY104614722090563$50,000FMVTHERAPY ACCELERATION
CUTANEOUS LYMPHOMA FOUNDATION
PO BOX 374BIRMINGHAMMI4801203743834431353$100,000FMVTHERAPY ACCELERATION
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVE BELFER 1108BRONXNY104614722090563$126,493ACCRUALRESEARCH GRANTS
ATRIUM HEALTH FOUNDATION
208 EAST BOULEVARDCHARLOTTENC282035660604813$137,500ACCRUALRESEARCH GRANTS
BAYLOR COLLEGE OF MEDICINE
P O BOX 301207DALLASTX7530312077416138783$431,695ACCRUALRESEARCH GRANTS
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROADDUARTECA910109534322103$1,970,068ACCRUALRESEARCH GRANTS
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253SAN FRANCISCOCA9414442539411563653$743,950ACCRUALRESEARCH GRANTS
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413BOSTONMA0224144130427744413$50,783ACCRUALRESEARCH GRANTS
BOSTON UNIVERSITY RESEARCH ACCOUNTI
PO BOX 28763NEW YORKNY1008787630421035473$267,347FMVTHERAPY ACCELERATION
BRIGHAM AND WOMEN'S HOSPITAL
PO BOX 3149BOSTONMA0224131490423129093$38,500ACCRUALRESEARCH GRANTS
CHILDREN'S RESEARCH INSTITUTE
801 ROEDER RD SUITE 500SILVER SPRINGMD209105216404033$150,000ACCRUALRESEARCH GRANTS
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVENUE ML 4900CINCINATTIOH452293108339363$273,450ACCRUALRESEARCH GRANTS
CLEVELAND CLINIC FOUNDATION
9500 EUCLID AVENUECLEVELANDOH441953407145853$70,000ACCRUALRESEARCH GRANTS
DANA-FARBER CANCER INSTITUTE
450 BROOKLINE AVENUEBOSTONMA022150422630403$1,764,949ACCRUALRESEARCH GRANTS
EMORY UNIVERSITY
PO BOX 935084ATLANTAGA3119350845821379933$1,200,000ACCRUALRESEARCH GRANTS
FRED HUTCHINSON CANCER RESEARCH CEN
P O BOX 19024SEATTLEWA9810910242371560713$898,385ACCRUALRESEARCH GRANTS
HACKENSACK MERIDIAN HEALTH
40 PROSPECT AVENUEHACKENSACKNJ076012214872783$38,500ACCRUALRESEARCH GRANTS
HARVARD MEDICAL SCHOOL
PO BOX 415649BOSTONMA0224156490421035803$21,000ACCRUALRESEARCH GRANTS
ICAHN SCHOOL OF MEDICINE AT MOUNT S
ONE GUSTAVE L LEVY PLACE BOX 350NEW YORKNY100291361711973$147,000ACCRUALRESEARCH GRANTS
INDIANA UNIVERSITY
PO BOX 78000DETROITMI4827808673560189403$70,000ACCRUALRESEARCH GRANTS
INTERNATIONAL WALDENSTROM'S MACROGL
6144 CLARK CENTER AVESARASOTAFL342385417844263$125,000ACCRUALRESEARCH GRANTS
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FLNEW YORKNY100221316239783$2,012,000ACCRUALRESEARCH GRANTS
MASSACHUSETTS GENERAL HOSPITAL
PO BOX 414876BOSTONMA0224148760415646553$53,750ACCRUALRESEARCH GRANTS
MAYO CLINIC ROCHESTER
PO BOX 860334MINNEAPOLISMN5548603344160117023$70,000ACCRUALRESEARCH GRANTS
MONTEFIORE MEDICAL CENTER
111 EAST 210TH STREETBRONXNY104671317401143$70,000ACCRUALRESEARCH GRANTS
MYELOPROLIFERATIVE NEOPLASMS RESEAR
180 N MICHIGAN AVENUECHICAGOIL606013643309673$200,000ACCRUALRESEARCH GRANTSSUITE 1870
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026BOSTONMA0224141501355623083$799,514ACCRUALRESEARCH GRANTS
NORTHWESTERN UNIVERSITY
633 CLARK - ROOM G547EVANSTONIL602083621678173$131,950ACCRUALRESEARCH GRANTS
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROADPORTLANDOR972392370831143$43,750ACCRUALRESEARCH GRANTSMAIL CODE L106
PERELMAN SCHOOL OF MEDICINE AT THE
3451 WALNUT STREET FRANKLIN BLDG P-PHILADELPHIAPA1910462052313526853$30,417ACCRUALRESEARCH GRANTS
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131PITTSBURGHPA1525121313860063093$330,000ACCRUALRESEARCH GRANTS
ROCKEFELLER UNIVERSITY
1230 YORK AVENUE BOX 82NEW YORKNY100211316241583$70,000ACCRUALRESEARCH GRANTS
ROOT DIAGNOSTICS
400 E 52ND STNEW YORKNY100228446874543$60,000ACCRUALRESEARCH GRANTS
SANFORD BURNHAM PREBYS MEDICAL DISC
10901 NORTH TORREY PINES ROADLA JOLLACA920375101971083$73,862ACCRUALRESEARCH GRANTS
SEATTLE CHILDREN'S HOSPITAL
4800 SAND POINT WAY NESEATTLEWA981059111565193$143,892ACCRUALRESEARCH GRANTS
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338NEW YORKNY100871319242363$1,318,700ACCRUALRESEARCH GRANTS
ST JUDE CHILDREN'S RESEARCH HOSPIT
PO BOX 1000 DEPT 949MEMPHISTN3814809496206460123$288,749ACCRUALRESEARCH GRANTS
TEMPLE UNIVERSITY
PO BOX 824242PHILADELPHIAPA1918242422313659713$70,000ACCRUALRESEARCH GRANTS
THE CHILDREN'S HOSPITAL OF PHILADEL
PO BOX 8500PHILADELPHIAPA1917814572313521663$194,975ACCRUALRESEARCH GRANTS
THE JOHNS HOPKINS UNIVERSITY SCHOOL
12529 COLLECTIONS CENTER DRIVECHICAGOIL606935205951103$170,000ACCRUALRESEARCH GRANTS
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD 4TH FLOORCOLUMBUSOH4321010163160259863$36,515ACCRUALRESEARCH GRANTSATTN RICHARD BRADBURY
THE RECTOR AND VISITORS OF THE UNIV
PO BOX 400195CHARLOTTESVILLEVA2290441955460017963$300,000ACCRUALRESEARCH GRANTS
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009LA JOLLACA9209300099560061443$500,000ACCRUALRESEARCH GRANTS
THE REGENTS OF THE UNIVERSITY OF CA
PO BOX 748872LOS ANGELESCA9007448729460364933$100,000ACCRUALRESEARCH GRANTS
THE SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROADLA JOLLACA920373304359543$21,000ACCRUALRESEARCH GRANTS
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$70,000ACCRUALRESEARCH GRANTS
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789NEW YORKNY1008797891355980933$127,050ACCRUALRESEARCH GRANTS
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREET FRANKLIN BLDG PPHILADELPHIAPA1910462052313526853$2,144,998ACCRUALRESEARCH GRANTS
THE UNIVERSITY OF ALABAMA AT BIRMIN
1530 3RD AVENUE SOUTH SUITE 1170BIRMINGHAMAL3529401116360053963$173,450ACCRUALRESEARCH GRANTS
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL606373621771393$110,000ACCRUALRESEARCH GRANTS
THE UNIVERSITY OF NORTH CAROLINA AT
PO BOX 402420ATLANTAGA3038424205660013933$522,490ACCRUALRESEARCH GRANTS
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266HOUSTONTX7721042667460011183$569,473ACCRUALRESEARCH GRANTS
THE UNIVERSITY OF TEXAS SOUTHWESTER
PO BOX 841753DALLASTX7528417537560028683$66,000ACCRUALRESEARCH GRANTS
THE UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145SALT LAKE CITYUT8411290038760005253$38,500ACCRUALRESEARCH GRANTSACCOUNTS PAYABLE
THE V FOUNDATION
14600 WESTON PARKWAYCARYNC27513133705951$39,707FMVTHERAPY ACCELERATION
TUFTS MEDICAL CENTER
800 WASHINGTON STREET 453BOSTONMA021110421036343$250,000ACCRUALRESEARCH GRANTS
UNIVERSITY OF ARKANSAS FOR MEDICAL
4301 W MARKHAM SLOT 545LITTLE ROCKAR722057160567743$56,299ACCRUALRESEARCH GRANTS
UNIVERSITY OF CALIFORNIA IRVINE
300 UNIVERSITY TOWER UNIVERSITY OFIRVINECA9269776009525401173$70,000ACCRUALRESEARCH GRANTS
UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092CHICAGOIL60637362177139$1,078,388FMVTHERAPY ACCELERATION
UNIVERSITY OF COLORADO DENVER ANSC
PO BOX 6508AURORACO800458460005553$567,200ACCRUALRESEARCH GRANTS
UNIVERSITY OF COLORADO-DENVER
12700 E 19TH AVENUEAURORACO800458460005553$150,000ACCRUALRESEARCH GRANTS
UNIVERSITY OF FLORIDA
P O BOX 113001GAINESVILLEFL3261130015960020523$1,638,093ACCRUALRESEARCH GRANTS
UNIVERSITY OF KENTUCKY
109 KINKEAD HALLLEXINGTONKY4050600016160336933$20,998ACCRUALRESEARCH GRANTS
UNIVERSITY OF MIAMI
PO BOX 405803ATLANTAGA3038458035906244583$1,059,500ACCRUALRESEARCH GRANTS
UNIVERSITY OF NOTRE DAME
511 MAIN BUILDINGNOTRE DAMEIN465563508681883$70,000ACCRUALRESEARCH GRANTS
UNIVERSITY OF SOUTHERN CALIFORNIA
FILE NO 52095LOS ANGELESCA900899516423943$55,000ACCRUALRESEARCH GRANTS
UNIVERSITY OF VIRGINIA
PO BOX 400195CHARLOTTESVILLEVA2290441952371734113$38,500ACCRUALRESEARCH GRANTS
UNIVERSITY OF WISCONSIN AT MADISON
500 LINCOLN DRIVEMADISONWI537063960064923$23,450ACCRUALRESEARCH GRANTS
VAN ANDEL RESEARCH INSTITUTE
333 BOSTWICK AVE NEGRAND RAPIDSMI495035220008203$38,500ACCRUALRESEARCH GRANTS
VANDERBILT UNIVERSITY MEDICAL CENTE
DEPT 1236 PO BOX 121236DALLASTX753126204768223$161,786ACCRUALRESEARCH GRANTS
WASHINGTON UNIVERSITY IN ST LOUIS
700 ROSEDALE AVENUEST LOUISMO631124306536113$220,000ACCRUALRESEARCH GRANTS
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034ST LOUISMO6311214084306536113$110,000ACCRUALRESEARCH GRANTS
YALE UNIVERSITY
PO BOX 1873NEW HAVENCT0652018730606469733$79,416ACCRUALRESEARCH GRANTS
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD 4TH FLOORCOLUMBUSOH432101016316025986$1,040,819FMVTHERAPY ACCELERATIONATTN RICHARD BRADBURY
FieldValueIRS element (for citing)
Total501c3 Org72Total501c3OrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (11 entries)

Grant TypeGrantTypeTxtRecipientRecipientCntCash GrantCashGrantAmt
COPAY ASSISTANCE CLL2575$13,147,123
COPAY ASSISTANCE LYMPHOMA2781$11,246,287
COPAY ASSISTANCE MDS2461$12,902,049
COPAY ASSISTANCE MYELOMA10778$76,262,649
COPAY ASSISTANCE MANTEL533$1,422,419
COPAY ASSISTANCE WALDENST480$2,943,937
COPAY ASSISTANCE ALL46$100,920
COPAY ASSISTANCE AML2517$13,028,104
COPAY ASSISTANCE CML79$157,893
PATIENT TRAVEL ASSISTANC6408$3,204,010
PATIENT AID68837$8,372,492

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE I, PAGE 1, PART I, LINE 2FormAndLineReferenceDesc
ExplanationFIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeYes (X)CompensationCommitteeInd
Independent ConsultantYes (X)IndependentConsultantInd
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentYes (true)SeverancePaymentInd
Supplemental Nonqual Rtr PlanYes (true)SupplementalNonqualRtrPlanInd
Equity Based Comp ArrngmfalseEquityBasedCompArrngmInd
Comp Based On Revenue Of Flng OrgfalseCompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related OrgsfalseCompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng OrgfalseCompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd OrgsfalseCompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (true)AnyNonFixedPaymentsInd
Initial Contract ExceptionfalseInitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (10 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtBonus Filing OrganizationBonusFilingOrganizationAmountOther Compensation Filing OrgOtherCompensationFilingOrgAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmt
LOUIS J DEGENNARO
PRESIDENT & CEO$449,491$170,259$162,681$17,640$25,814$825,885
GWEN NICHOLS
EVP CHIEF MED OFFICE$396,280$79,786$25,305$9,800$30,369$541,540
KATHY GRIESENBECK
EVP CHIEF REL OFFICE$306,937$49,276$28,356$14,000$24,373$422,942
LEE M GREENBERGER
SVP CHIEF SCIEN OFFI$297,708$59,959$15,997$14,000$35,055$422,719
VANESSA WHITE
SVP CHIEF ADV OFF$348,253$42,367$1,176$20,854$412,650
COKER POWELL
EVP PROD CAMP DEV$290,992$47,947$19,715$9,800$39,400$407,854
ROSEMARIE ALOFFREDO - END 3312019
CHIEF FIN OFFICER$99,101$286,599$5,956$4,275$395,931
THOMAS OSGOOD
EVP CHIEF HUMAN RESO$299,662$45,781$2,873$9,800$20,896$379,012
GORDON MILLER JR
EVP CHIEF FIN OFFICE$288,843$40,547$2,518$14,000$25,930$371,838
ROBERT BECK - END 7519
EVP CHIEF OPER OFFIC$219,752$109,375$21,376$1,050$2,271$353,824

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
SCHEDULE J, PAGE 1, PART I, LINE 4LOUIS J. DEGENNARO 0 149,727 0 ROSEMARIE A.LOFFREDO - END 3/31/2019 286,599 0 0
SCHEDULE J, PAGE 1, PART I, LINE 7BONUSES WERE PAID BASED ON THE ACHIEVEMENT IF THE EMPLOYEE INDIVIDUAL PERFORMANCE. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B) (II).

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution194ContributionCnt
Noncash Contributions Rpt F990$1,678,625NoncashContributionsRptF990Amt
Method Of Determining RevenuesFAIR MARKET VALUEMethodOfDeterminingRevenuesTxt

Food Inventory FoodInventoryGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution81ContributionCnt

Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)

Non Cash CheckboxNonCashCheckboxIndDescDescContributionContributionCntNoncash Contributions Rpt F990NoncashContributionsRptF990Amt
Yes (X)PRINTED ITEMS16
Yes (X)VARIOUS OTHER69$932,822
FieldValueIRS element (for citing)
Any Property That Must Be HeldfalseAnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (true)ReviewProcessUnusualNCGiftsInd
Third Parties UsedfalseThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE M, PAGE 2, PART IIFormAndLineReferenceDesc
ExplanationPART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (11 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PAGE 2, PART III, LINE 4AA) RESEARCH PROGRAMS WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2020, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 8 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 26.8 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. AT THE END OF 2020, THE BEAT AML TRIAL HAD ENROLLED 1,000 PATIENTS. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE- EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2018, FOR THE SEVENTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FO
FORM 990, PAGE 2, PART III, LINE 4BB) PATIENT & COMMUNITY SERVICES SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER, LLS WEBSITE AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL. IN 2020, 615,299 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 12,296 FACT SHEETS WERE ORDERED. ADDITIONALLY, THERE WERE 131,924 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. EDUCATION MATERIALS ARE AVAILABLE TO DOWNLOAD OR ORDER AT WWW.LLS.ORG/BOOKLETS. MANY MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH, AND SELECT MATERIALS ARE AVAILABLE IN ADDITIONAL LANGUAGES. FINANCIAL ASSISTANCE IN 2020, A COMBINED 142,351,684 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAM (131,293,984), THE LLS SUSAN LANG PATIENT TRAVEL ASSISTANCE PROGRAM (2,667,500), THE LLS URGENT NEED PROGRAM (1,833,500), LLS PATIENT AID PROGRAM (1,722,200), AND THE COVID-19 PATIENT FINANCIAL AID PROGRAM (4,834,500). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2020, 131,293,984 WAS PROVIDED TO 22,253 PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2020, 2,667,500 WAS PROVIDED TO 5,335 PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM. URGENT NEED PROGRAM THE URGENT NEED PROGRAM WAS ESTABLISHED TO HELP PEDIATRIC AND YOUNG ADULT BLOOD CANCER PATIENTS, OR ADULT BLOOD CANCER PATIENTS ENROLLED IN CLINICAL TRIALS, WHO ARE IN ACUTE FINANCIAL NEED. THE PROGRAM PROVIDES ELIGIBLE PATIENTS ASSISTANCE FOR NON-MEDICAL EXPENSES INCLUDING RENT, MORTGAGE, LODGING, UTILITIES, CHILDCARE, ELDER CARE, FOOD, TRANSPORTATION, CAR REPAIR, CAR INSURANCE, PHONE SERVICE, AND ACUTE DENTAL WORK RELATED TO TREATMENT. IN 2020, 1,833,500 WAS PROVIDED TO 3,667 PATIENTS THROUGH THE LLS URGENT NEED PROGRAM. PATIENT AID PROGRAM THE PATIENT AID PROGRAM PROVIDES FINANCIAL ASSISTANCE TO BLOOD CANCER PATIENTS. ELIGIBLE PATIENTS WILL RECEIVE A ONE-TIME 100 STIPEND TO HELP OFFSET EXPENSES. IN 2020, 1,722,200 WAS PROVIDED TO 17,222 PATIENTS THROUGH THE LLS PATIENT AID PROGRAM. LLS COVID-19 PATIENT FINANCIAL AID PROGRAM LLS ESTABLISHED THE LLS COVID-19 PATIENT FINANCIAL AID PROGRAM TO HELP ELIGIBLE BLOOD CANCER PATIENTS EXPERIENCING FINANCIAL HARDSHIP DUE TO THE PANDEMIC. ELIGIBLE PATIENTS WILL RECEIVED A ONE-TIME 250 STIPEND TO HELP OFFSET EXPENSES. IN 2020, 4,834,500 WAS PROVIDED TO 19,338 PATIENTS THROUGH THE COVID-19 PATIENT FINANCIAL AID PROGRAM. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY EDUCATION & SERVICES STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL; THIS YEAR, MOST WERE IN-PERSON BUT ONE WAS VIRTUAL DUE TO COVID-19. IN 2020, EIGHT BCC CONFERENCES WERE HELD WITH 4,065 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016 TO HONOR THE MEMORY OF MICHAEL GARIL, WHO WAS DIAGNOSED WITH ALL IN 1974 AT THE AGE OF SEVEN. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2020, THERE WERE APPROXIMATELY 75,472 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2020 LLS SUPPORTED OR HOSTED 127 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS ALSO HOSTED 7 ONLINE NATIONAL CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2020, 5,246 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS AND CAREGIVERS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT/CAREGIVER- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE PATIENT/CAREGIVER TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,700 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2020.
FORM 990, PAGE 2, PART III, LINE 4CC) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE HIGHLY TRAINED ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS MAY ALSO REFER PATIENTS AND CAREGIVERS TO A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER (CTSC). THE NURSES IN THE CTSC HAVE EXPERTISE IN THE BLOOD CANCERS AND PROVIDE PATIENTS AND THEIR CAREGIVERS WITH COMPREHENSIVE NAVIGATION TO FIND AND ENROLL IN AN APPROPRIATE CLINICAL TRIAL. AS PART OF THIS PROCESS, THE NURSES WORK CLOSELY WITH INFORMATION SPECIALISTS TO ADDRESS RESOURCE BARRIERS TO CLINICAL TRIAL ENROLLMENT. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2020: - 25,202 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 14,580 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. -779 PATIENTS WORKED WITH A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 20% OF PATIENTS ASSISTED ENROLLED ON A CLINICAL TRIAL. LLS OFFERS PATIENTS AND CAREGIVERS FREE ONE-ON-ONE PHONE AND EMAIL CONSULTATIONS WITH A REGISTERED DIETITIAN WITH EXPERTISE IN ONCOLOGY NUTRITION. THIS SERVICE IS AVAILABLE TO ALL CANCER PATIENTS AND THEIR CAREGIVERS. IN FY 20 NEARLY 1,000 CONSULTATIONS WERE PROVIDED. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING FINANCIAL ASSISTANCE, INFORMATION SPECIALISTS, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH (AND ADDITIONAL LANGUAGES FOR SELECT MATERIALS), PERSONALIZED CLINICAL TRIAL NAVIGATION BY A REGISTERED NURSE, PERSONALIZED NUTRITION CONSULTATIONS BY A REGISTERED DIETICIAN AND CONTINUING EDUCATION PROGRAMS FOR HEALTHCARE PROFESSIONALS. NATIONAL TELEPHONE/WEB EDUCATION PROGRAMS LLS CONDUCTS TELEPHONE-WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES AS WELL AS SURVIVORSHIP ISSUES. PROGRAM PARTICIPANTS ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS DELIVERED BY WORLD RENOWNED CLINICAL EXPERTS. UPCOMING AND ARCHIVED PROGRAMS ARE POSTED AT WWW.LLS.ORG/WEBCASTS. IN FY 2020: -LLS CONDUCTED 16 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 12,713 PARTICIPANTS -THERE WERE 51,125 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 25,367 VIRTUAL LECTURE VIEWS; 21,427 PODCAST DOWNLOADS; AND 60,234 VIDEO VIEWS.
FORM 990, PAGE 2, PART III, LINE 4DD) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2020: -LLS PROVIDED 9 CME/CE-GRANTING IN-PERSON EDUCATIONAL PROGRAMS, WITH 1,407 HEALTHCARE PROFESSIONALS IN ATTENDANCE. --THERE WERE 36,338 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 22,394 VIRTUAL LECTURE VIEWS AND 11,433 PODCAST DOWNLOADS.
FORM 990, PART V, LINE 4BCANADA
FORM 990, PAGE 6, PART VI, LINE 11BTHE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS.
FORM 990, PAGE 6, PART VI, LINE 12CALL EMPLOYEES, VOLUNTEERS, CONSULTANTS, TEMPORARY EMPLOYEES, LOCAL BOARD MEMBERS, AND MEMBERS OF THE NATIONAL BOARD OF DIRECTORS ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL CONFLICT OF INTEREST DISCLOSURE FORMS ARE REVIEWED BY THE LEGAL DEPARTMENT AND, IF DEEMED NECESSARY, ESCALATED TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR FURTHER REVIEW, EVALUATION, AND/OR MANAGEMENT OF ANY ACTUAL OR APPARENT CONFLICTS OF INTEREST.
FORM 990, PAGE 6, PART VI, LINE 15ATHE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THEIR DECISION IS INCLUDED IN THE APPROPRIATE MINUTES OF THE MEETING IN WHICH APPROVAL WAS GIVEN. IN 2020, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES.
FORM 990, PAGE 6, PART VI, LINE 15BIN 2020, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS.
FORM 990, PAGE 6, PART VI, LINE 17ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
FORM 990, PAGE 6, PART VI, LINE 19THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp (13 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdTotal IncomeTotalIncomeAmtEnd Of Year AssetsEndOfYearAssetsAmtBusiness Name Line1DirectControllingEntityName/BusinessNameLine1Txt
BEAT AML LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNY$17,268,216$9,320,277LLS
LLS PEDAL INITIATIVE LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNY$320,000$265,551LLS
LLS TAP FORTY SEVEN LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNY$24,937,943LLS
LLS TAP MIRAGEN LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNY$673,064LLS
LLS TAP X4 LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNY$2,796,000LLS
LLS TAP LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNY$24,585,310$3,469,064LLS
LLS TAP CONSTELLATION LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNYLLS
LLS TAP AFFIRMED LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNYLLS
LLS TAP SUTRO LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNYLLS
LLS TAP JOHNS HOPKINS LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNYLLS
LLS TAP SELVITA LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNYLLS
LLS TAP VERASTEM LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNYLLS
LLS TAP KDAC LLC
3 INTERNATIONAL DRIVERYE BROOKNY10573RESEARCHNYLLS

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdEINEINPrimary ActivitiesPrimaryActivitiesTxtLegal Domicile StateLegalDomicileStateCdExempt Code SectionExemptCodeSectionTxtPublic Charity StatusPublicCharityStatusTxtBusiness Name Line1DirectControllingEntityName/BusinessNameLine1TxtControlled OrganizationControlledOrganizationIndAddress Line1ForeignAddress/AddressLine1TxtCityForeignAddress/CityNmCountryForeignAddress/CountryCdForeign PostalForeignAddress/ForeignPostalCdLegal Domicile Foreign CountryLegalDomicileForeignCountryCd
THE LLS RESEARCH PROGRAMS INC
3 INTERNATIONAL DRIVERYE BROOKNY10573133470494PART VIIDE501C312ALLS INCYes (true)
THE LLS RESEARCH FOUNDATION
3 INTERNATIONAL DRIVERYE BROOKNY10573133709252PART VIIDE501C312ALLS INCYes (true)
THE LLS OF CANADA
PART VIINAfalse804 2 LANSING SQUARETORONTOCAM2J4P8CA
FieldValueIRS element (for citing)
Receipt Of Int Annts Rnts RyltsfalseReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth OrgfalseGiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth OrgfalseGiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other OrgfalseLoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth OrgfalseLoansOrGuaranteesFromOthOrgInd
Div Related OrganizationfalseDivRelatedOrganizationInd
Asset Sale To Other OrgfalseAssetSaleToOtherOrgInd
Asset Purchase From Other OrgfalseAssetPurchaseFromOtherOrgInd
Asset ExchangefalseAssetExchangeInd
Rental Of Facilities To Oth OrgfalseRentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth OrgfalseRentalOfFcltsFromOthOrgInd
Perform Of Services For Oth OrgfalsePerformOfServicesForOthOrgInd
Perform Of Services By Other OrgfalsePerformOfServicesByOtherOrgInd
Sharing Of FacilitiesfalseSharingOfFacilitiesInd
Paid Employees SharingfalsePaidEmployeesSharingInd
Reimbursement Paid To Other OrgfalseReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other OrgYes (true)ReimbursementPaidByOtherOrgInd
Transfer To Other OrgfalseTransferToOtherOrgInd
Transfer From Other OrgfalseTransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp

Other Organization Name OtherOrganizationName

FieldValueIRS element (for citing)
Business Name Line1LLS CANADABusinessNameLine1Txt
FieldValueIRS element (for citing)
Transaction TypeQTransactionTypeTxt
Involved$196,278InvolvedAmt
Method Of Amount DeterminationCOSTMethodOfAmountDeterminationTxt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE RFormAndLineReferenceDesc
ExplanationTHE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., BUT IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.ExplanationTxt

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.